BTKis in WM: ibrutinib versus zanubrutinib and the use of non-covalent BTKis VJHemOnc – Video Journal of Hematology & HemOnc 1:22 1 day ago 29 Далее Скачать
ASPEN: zanubrutinib versus ibrutinib in patients with WM VJHemOnc – Video Journal of Hematology & HemOnc 6:05 4 years ago 293 Далее Скачать
The role of covalent and non-covalent BTKIs in the MCL treatment landscape VJHemOnc – Video Journal of Hematology & HemOnc 2:38 3 months ago 83 Далее Скачать
Tolerability of next-generation BTK inhibitors: acalabrutinib, zanubrutinib and pirtobrutinib VJHemOnc – Video Journal of Hematology & HemOnc 3:31 1 year ago 1 185 Далее Скачать
The efficacy of zanubrutinib versus ibrutinib in patients with WM harboring various mutations VJHemOnc – Video Journal of Hematology & HemOnc 1:44 1 year ago 313 Далее Скачать
Non-covalent vs covalent BTK inhibitors in CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:23 2 years ago 755 Далее Скачать
Post hoc analysis comparing the safety profile of zanubrutinib vs ibrutinib in B-cell malignancies VJHemOnc – Video Journal of Hematology & HemOnc 1:08 1 year ago 161 Далее Скачать
Progress With BTK Inhibitors: A Journey Through the Mechanisms of Covalent and Noncovalent Options PeerView Oncology 22:36 2 years ago 2 235 Далее Скачать
The potential role of non-covalent BTKis in mitigating covalent BTKi resistance VJHemOnc – Video Journal of Hematology & HemOnc 1:24 2 days ago 68 Далее Скачать
Pirtobrutinib shows efficacy in BTKi refractory Waldenström’s macroglobulinemia patients VJHemOnc – Video Journal of Hematology & HemOnc 2:51 1 year ago 86 Далее Скачать
Comparing BTK Inhibitors in Patients With B-Cell Malignancies Targeted Oncology 1:01 4 years ago 248 Далее Скачать
Identifying Differences Between BTK Inhibitors for B-Cell Malignancies Targeted Oncology 1:00 4 years ago 151 Далее Скачать
An overview of the management of patients with R/R Waldenström’s macroglobulinemia VJHemOnc – Video Journal of Hematology & HemOnc 2:09 3 months ago 80 Далее Скачать
Choosing the best BTK inhibitor for managing CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:59 1 year ago 561 Далее Скачать
Zanubrutinib for ibrutinib/acalabrutinib intolerant R/R B-cell malignancies VJHemOnc – Video Journal of Hematology & HemOnc 1:33 3 years ago 356 Далее Скачать
Dr. Woyach on BTK Inhibition and the Mechanism of Action of Ibrutinib Targeted Oncology 1:17 11 years ago 2 268 Далее Скачать
Novel PD-1 inhibitor and BTK inhibitor combination: tislelizumab and zanubrutinib VJHemOnc – Video Journal of Hematology & HemOnc 0:57 6 years ago 469 Далее Скачать
Developments in the use of different classes of BTK inhibitors for CLL treatment VJHemOnc – Video Journal of Hematology & HemOnc 1:30 2 years ago 54 Далее Скачать
